Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 3, 2006, Pages 481-485

  Pro, Barbara ^a   Fayad, Luis ^a   McLaughlin, Peter ^a   Romaguera, Jorge ^a   Hagemeister, Fredrick B ^a   Rodriguez, Maria A ^a   Goy, Andre ^a   Loyer, Evelyn ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Non Hodgkin's lymphoma; Paclitaxel; Pegfilgrastim; Relapsed NHL; Topotecan

Indexed keywords

PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; MALE; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; PACLITAXEL; RECURRENCE; TOPOTECAN; TREATMENT OUTCOME;

EID: 30844469325     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500305802     Document Type: Article

References (13)

1. Hennessy, B and Hanrahan, E and Daly, P. (2004) Non-Hodgkin lymphoma: An update Lancet Oncol, 5, pp. 341-353.
2. Aparicio, J and Segura, A and Garcera, S and Oltra, A and Santaballa, A and Yuste, A and (1999) ESHAP is an active regimen for relapsing Hodgkin's disease Ann Oncol, 10, pp. 593-595.
3. King, K and Younes, A. (2000) Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma Semin Oncol, 27, pp. 14-22.
4. Kung, F and Harris, M and Krischer, J. (1999) Ifosfamide/carboplatin/ etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: A Pediatric Oncology Group phase II study Med Pediatr Oncol, 32, pp. 225-226.
5. Rodriguez, M and Cabanillas, F and Velasquez, W and Hagemeister, F and McLaughlin, P and Swan, F and Romaguera, J. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP J Clin Oncol, 13, pp. 1734-1741.
6. Moskowitz, C and Nimer, S and Zelenetz, A and Trippett, T and Hendrick, E and Filippa, D and (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model Blood, 97, pp. 616-623.
7. Younes, A and Preti, H and Hagemeister, F and McLaughlin, P and Romaguera, J and Rodriguez, M and (2001) Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma Ann Oncol, 12, pp. 923-927.
8. Crawford, J. (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia Semin Oncol, 30, pp. 24-30.
9. Holmes, F and O'Shaughnessy, J and Vukelja, S and Jones, S and Shogan, J and Savin, M and (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol, 20, pp. 727-731.
10. Green, M and Koelbl, H and Baselga, J and Galid, A and Guillem, V and Gascon, P and (2003) for the International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol, 14, pp. 29-35.
11. Vose, J and Crump, M and Lazarus, H and Emmanouilides, C and Schenkein, D and Moore, J and (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol, 21, pp. 514-519.
12. Harris, N and Jaffe, E and Diebold, J and Flandrin, G and Muller-Hermelink, H and Vardiman, J. (2000) Lymphoma classification-from controversy to consensus: The REAL, WHO Classification of lymphoid neoplasms Ann Oncol, 11(Suppl 1), pp. 3-10.
13. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol, 17, pp. 1244.